MedTrace Logo

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

NCT05588609 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-04-27

No results posted yet for this study

Summary

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses:

Group A: NRG1+ NSCLC Group B: mCRPC

Conditions

Interventions

DRUG

Afatinib Oral Tablet

anti epidermal growth factor receptor (EGFR)/HER2 agent

DRUG

Enzalutamide Pill

second-generation androgen receptor antagonist

DRUG

Abiraterone acetate tablets

androgen synthesis inhibitor

BIOLOGICAL

MCLA-128

full length IgG1 bispecific antibody targeting HER2 and HER3

Sponsors & Collaborators

  • Partner Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-17
Primary Completion
2025-07-03
Completion
2025-07-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05588609 on ClinicalTrials.gov